Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Respiratory
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
1 programIdiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes RegistryN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Boehringer IngelheimIdiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Clinical Trials (1)
Total enrollment: 3,000 patients across 1 trials
NCT01915511Boehringer IngelheimIdiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Start: Jun 2014Est. completion: Jan 20313,000 patients
N/ARecruiting
Related Jobs in Respiratory
Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)
Krystal Biotech
1h ago
$185K - $215K/yr
Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)
Krystal Biotech
1h ago
$185K - $215K/yr
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Marketing Intern – Vertex Iberia (Spain)
Vertex Pharmaceuticals
Madrid, Spain
Yesterday
Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)
Sanofi
Berlin
Yesterday
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 3,000 patients
1 companies competing in this space